Analyst Consensus ?
ConsensusHold35 ratings
Bullish1131.4%
Neutral2057.2%
Bearish411.4%
Dow Inc. · DOW · FY2024 Q3 · Calendar Q4 2024
Dow sees Americas strength offset soft Europe and China demand
Dow’s low-cost Americas footprint and resilient packaging demand supported the quarter, but the outlook remains balanced by weak conditions in Europe and China, trade exposure and execution risks.
Reported Before market openNYSEBasic Materials
$24.55B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$0.47
Consensus $0.46
EPS surprise
+2.8%
Reported versus consensus
Reported revenue
$10.88B
Consensus $10.65B
Revenue surprise
+2.1%
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
-1.0%
Event window
SPY move
+0.2%
Same window
Abnormal move
-1.2%
Stock minus SPY
Volume
1.4×
Versus trailing sessions
Subsequent drift
-12.1%
Up to 20 sessions
DOWSPY benchmark
Ask FN2 about DOW FY2024 Q3
Transcript, numbers and history already loaded
Why did DOW fall 1.0% after beating EPS estimates in FY2024 Q3?What changed in DOW's guidance and outlook in FY2024 Q3?Give me the bull and bear case for DOW after FY2024 Q3 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Management highlighted year-over-year volume growth, a strategic review of selected European polyurethane assets, the Circulus recycling acquisition and a hydrogen supply agreement supporting Path2Zero.
Guidance delta
Maintained; management’s Q4 outlook called for year-over-year earnings growth with flat pricing and a Texas-8 ramp-up contribution.
Key takeaways
- Americas feedstock advantages continued to support competitiveness and pricing.
- Packaging and functional polymer demand remained comparatively resilient in North America.
- European and Chinese demand stayed soft, increasing the importance of portfolio and cost actions.
- Cash generation and liquidity support planned growth investments and capital flexibility.
Management priorities
- Improve returns through the European polyurethane asset review.
- Advance Path2Zero and its hydrogen supply arrangement.
- Expand silicone capacity and develop circular recycled-resin products.
- Execute the Transform the Waste circularity strategy.
Follow DOW with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$33.99Previous close
$20Low
$46.98Average
$81High
Latest persisted target per named analyst; persisted previous close from FN2's market snapshot as of Oct 27, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Wells Fargo | Overweight | Overweight | Maintain | Oct 23, 2026 |
| UBS | Neutral | Neutral | Maintain | Oct 23, 2026 |
| RBC Capital | Sector Perform | Sector Perform | Maintain | Oct 23, 2026 |
| Citigroup | Neutral | Neutral | Maintain | Oct 23, 2026 |
| B of A Securities | Neutral | Underperform | Upgrade | Oct 19, 2026 |
| Mizuho | Neutral | Neutral | Maintain | Oct 1, 2026 |
| JP Morgan | Overweight | Overweight | Maintain | Jul 24, 2026 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | Jul 20, 2026 |
| BMO Capital | Market Perform | Market Perform | Maintain | Jul 6, 2026 |
| Alembic Global | Overweight | Overweight | Maintain | Jul 2, 2026 |
| Argus Research | Buy | Hold | Upgrade | May 13, 2026 |
| Jefferies | Hold | Hold | Maintain | Mar 10, 2026 |
| Fermium Research | Buy | Hold | Upgrade | Mar 9, 2026 |
| Keybanc | Overweight | Sector Weight | Upgrade | Mar 4, 2026 |
| Goldman Sachs | Neutral | Neutral | Maintain | Oct 29, 2025 |
| Evercore ISI Group | In Line | Outperform | Downgrade | Jul 25, 2025 |
| Barclays | Equal Weight | Equal Weight | Maintain | Apr 24, 2025 |
| Piper Sandler | Neutral | Neutral | Maintain | Apr 7, 2025 |
| Deutsche Bank | Hold | Hold | Maintain | Sep 12, 2024 |
| Credit Suisse | Underperform | Neutral | Downgrade | Jun 22, 2022 |
| Wolfe Research | Peer Perform | Underperform | Upgrade | Apr 19, 2022 |
| Bernstein | Market Perform | Outperform | Downgrade | Nov 13, 2020 |
| Truist Securities | Buy | Buy | Maintain | Sep 21, 2020 |
| HSBC | Reduce | Hold | Downgrade | Sep 16, 2020 |
| SunTrust Robinson Humphrey | Buy | Buy | Maintain | Jul 28, 2020 |
| ScotiaBank | Sector Perform | Sector Perform | Maintain | Jul 24, 2020 |
| Nomura | Buy | Buy | Maintain | Sep 18, 2019 |
| Bank of America | Underperform | Neutral | Downgrade | Aug 16, 2019 |
| Susquehanna | Neutral | Positive | Downgrade | Jul 29, 2019 |
| Argus | Buy | Hold | Upgrade | May 5, 2018 |
| CLSA | Underperform | Outperform | Downgrade | Jul 6, 2016 |
| Macquarie | Outperform | Outperform | Maintain | Jun 22, 2015 |
| Gilford Securities | Neutral | Sell | Upgrade | Jan 28, 2015 |
| Atlantic Equities | Neutral | Overweight | Downgrade | Nov 28, 2014 |
| The Oxen Group | Hold | Hold | Maintain | Apr 4, 2012 |
Named analyst price targets
Upside is calculated against the persisted previous close $33.99. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| UBS | Joshua Spector | $33 | $32.28 | -2.9% | Oct 23, 2026 |
| RBC Capital | Analyst unavailable | $32 | $31.46 | -5.9% | Oct 23, 2026 |
| Mizuho Securities | Analyst unavailable | $33 | $31.81 | -2.9% | Oct 23, 2026 |
| Barclays | Analyst unavailable | $30 | $28.12 | -11.7% | Oct 12, 2026 |
| Mizuho Securities | Analyst unavailable | $32 | $27.54 | -5.9% | Oct 1, 2026 |
| UBS | Analyst unavailable | $30 | $28.1 | -11.7% | Sep 25, 2026 |
| Deutsche Bank | Analyst unavailable | $32 | $29.44 | -5.9% | Sep 17, 2026 |
| UBS | Analyst unavailable | $32 | $29.36 | -5.9% | Jul 24, 2026 |
| Morgan Stanley | Analyst unavailable | $39 | $30.04 | +14.7% | Jul 20, 2026 |
| Goldman Sachs | Duffy Fischer | $34 | $29.68 | +0.0% | Jul 16, 2026 |
| BMO Capital | Analyst unavailable | $33 | $27.71 | -2.9% | Jul 6, 2026 |
| Wells Fargo | Analyst unavailable | $35 | $27.71 | +3.0% | Jul 3, 2026 |
| Alembic Global | Hassan Ahmed | $45 | $27.02 | +32.4% | Jul 2, 2026 |
| Mizuho Securities | John Roberts | $35 | $27.36 | +3.0% | Jul 1, 2026 |
| RBC Capital | Analyst unavailable | $28 | $27.36 | -17.6% | Jul 1, 2026 |
| UBS | Analyst unavailable | $37 | $34.14 | +8.9% | Jun 5, 2026 |
| Deutsche Bank | Analyst unavailable | $40 | $38.24 | +17.7% | Apr 27, 2026 |
| RBC Capital | Arun Viswanathan | $51 | $38.66 | +50.0% | Apr 27, 2026 |
| UBS | Analyst unavailable | $39 | $39.02 | +14.7% | Apr 24, 2026 |
| BMO Capital | Analyst unavailable | $46 | $38.22 | +35.3% | Apr 24, 2026 |
| Morgan Stanley | Analyst unavailable | $41 | $37.16 | +20.6% | Apr 21, 2026 |
| RBC Capital | Arun Viswanathan | $47 | $38.8 | +38.3% | Apr 10, 2026 |
| Alembic Global | Hassan Ahmed | $50 | $38.04 | +47.1% | Apr 9, 2026 |
| UBS | Analyst unavailable | $40 | $39.47 | +17.7% | Mar 26, 2026 |
| Fermium Research | Frank Mitsch | $38 | $34.31 | +11.8% | Mar 9, 2026 |
| Vertical Research | Analyst unavailable | $37 | $34.31 | +8.9% | Mar 9, 2026 |
| RBC Capital | Analyst unavailable | $40 | $34.31 | +17.7% | Mar 9, 2026 |
| KeyBanc | Aleksey Yefremov | $38 | $30.74 | +11.8% | Mar 4, 2026 |
| UBS | Joshua Spector | $28 | $27.56 | -17.6% | Jan 30, 2026 |
| Jefferies | Laurence Alexander | $28 | $27.16 | -17.6% | Jan 30, 2026 |
| RBC Capital | Analyst unavailable | $29 | $27.66 | -14.7% | Jan 16, 2026 |
| Mizuho Securities | John Roberts | $27 | $24.8 | -20.6% | Jan 8, 2026 |
| UBS | Analyst unavailable | $23 | $23.42 | -32.3% | Dec 23, 2025 |
| Deutsche Bank | David Begleiter | $25 | $22.98 | -26.4% | Dec 18, 2025 |
| Goldman Sachs | Analyst unavailable | $27 | $25.31 | -20.6% | Oct 29, 2025 |
| RBC Capital | Arun Viswanathan | $27 | $24.51 | -20.6% | Oct 24, 2025 |
| UBS | Joshua Spector | $25 | $24.51 | -26.4% | Oct 24, 2025 |
| Mizuho Securities | John Roberts | $25 | $24.51 | -26.4% | Oct 24, 2025 |
| Goldman Sachs | Analyst unavailable | $24 | $21.9 | -29.4% | Oct 17, 2025 |
| RBC Capital | Arun Viswanathan | $24 | $21.64 | -29.4% | Oct 14, 2025 |
| UBS | Analyst unavailable | $24 | $23.54 | -29.4% | Oct 6, 2025 |
| Mizuho Securities | Analyst unavailable | $26 | $23.69 | -23.5% | Oct 3, 2025 |
| Wells Fargo | Analyst unavailable | $30 | $24.14 | -11.7% | Sep 9, 2025 |
| Redburn Partners | Colin Isaac | $40 | $22.38 | +17.7% | Aug 5, 2025 |
| BMO Capital | John McNulty | $20 | $25.18 | -41.2% | Jul 29, 2025 |
| BMO Capital | Analyst unavailable | $22 | $26.87 | -35.3% | Jun 23, 2025 |
| RBC Capital | Arun Viswanathan | $30 | $30.02 | -11.7% | Apr 25, 2025 |
| Barclays | Michael Leithead | $32 | $29.76 | -5.9% | Apr 24, 2025 |
| Wells Fargo | Michael Sison | $40 | $28.2 | +17.7% | Apr 4, 2025 |
| RBC Capital | Arun Viswanathan | $44 | $40 | +29.4% | Dec 19, 2024 |
| Evercore ISI | Eric Boyes | $56 | $40.57 | +64.8% | Dec 17, 2024 |
| Wells Fargo | Michael Sison | $55 | $42.18 | +61.8% | Dec 10, 2024 |
| Piper Sandler | Charles Neivert | $60 | $46.49 | +76.5% | Nov 8, 2024 |
| Citigroup | Pat Cunningham | $52 | $50.15 | +53.0% | Sep 13, 2024 |
| RBC Capital | Arun Viswanathan | $55 | $50.26 | +61.8% | Sep 13, 2024 |
| Deutsche Bank | David Begleiter | $53 | $50.04 | +55.9% | Sep 12, 2024 |
| BMO Capital | John McNulty | $57 | $52.98 | +67.7% | Jul 26, 2024 |
| Piper Sandler | Charles Neivert | $64 | $53.06 | +88.3% | Jul 26, 2024 |
| RBC Capital | Arun Viswanathan | $57 | $53.06 | +67.7% | Jul 26, 2024 |
| Jefferies | Laurence Alexander | $55 | $55.44 | +61.8% | Jun 20, 2024 |
| Evercore ISI | Stephen Richardson | $62 | $58.7 | +82.4% | May 17, 2024 |
| UBS | John Roberts | $61 | $58.7 | +79.5% | May 16, 2024 |
| Piper Sandler | Charles Neivert | $68 | $57.61 | +100.1% | Apr 29, 2024 |
| Wells Fargo | Michael Sison | $68 | $58.26 | +100.1% | Apr 2, 2024 |
| J.P. Morgan | Jeffrey Zekauskas | $55 | $50.27 | +61.8% | Oct 17, 2023 |
| Morgan Stanley | Vincent Andrews | $54 | $55.62 | +58.9% | Jul 31, 2023 |
| Deutsche Bank | David Begleiter | $60 | $51.8 | +76.5% | Jun 13, 2023 |
| UBS | Analyst unavailable | $57 | $57.3 | +67.7% | Jan 11, 2023 |
| Wells Fargo | Analyst unavailable | $60 | $55.97 | +76.5% | Jan 9, 2023 |
| Citigroup | Analyst unavailable | $56 | $51.36 | +64.8% | Dec 15, 2022 |
| Fermium Research | Frank Mitsch | $50 | $45.77 | +47.1% | Oct 21, 2022 |
| Fermium Research | Analyst unavailable | $60 | $50.51 | +76.5% | Sep 9, 2022 |
| Mizuho Securities | Christopher Parkinson | $62 | $52.55 | +82.4% | Aug 2, 2022 |
| Morgan Stanley | Analyst unavailable | $60 | $51.58 | +76.5% | Jul 26, 2022 |
| Barclays | Analyst unavailable | $60 | $50.96 | +76.5% | Jul 11, 2022 |
| Credit Suisse | John Roberts | $49 | $51.8 | +44.2% | Jun 22, 2022 |
| Jefferies | Laurence Alexander | $81 | $54.77 | +138.3% | Jun 20, 2022 |
| Jefferies | Analyst unavailable | $74 | $55.58 | +117.7% | Jun 16, 2022 |
| Evercore ISI | Stephen Richardson | $68 | $69.06 | +100.1% | May 31, 2022 |
| Piper Sandler | Charles Neivert | $78 | $67.49 | +129.5% | May 24, 2022 |
| Barclays | Michael Leithead | $72 | $66.5 | +111.8% | May 2, 2022 |
| Argus Research | Bill Selesky | $81 | $67.81 | +138.3% | Apr 28, 2022 |
| Morgan Stanley | Analyst unavailable | $76 | $66.17 | +123.6% | Apr 25, 2022 |
| Deutsche Bank | David Begleiter | $74 | $69.51 | +117.7% | Apr 22, 2022 |
| J.P. Morgan | Analyst unavailable | $80 | $68.5 | +135.4% | Apr 22, 2022 |
| Wells Fargo | Analyst unavailable | $80 | $70.64 | +135.4% | Apr 22, 2022 |
| BMO Capital | Analyst unavailable | $76 | $69.51 | +123.6% | Apr 22, 2022 |
| RBC Capital | Analyst unavailable | $70 | $69.51 | +105.9% | Apr 22, 2022 |
| Citigroup | Analyst unavailable | $82 | $69.51 | +141.2% | Apr 22, 2022 |
| Mizuho Securities | Chris Parkinson | $68 | $69.51 | +100.1% | Apr 21, 2022 |
| Fermium Research | Frank Mitsch | $80 | $69.51 | +135.4% | Apr 21, 2022 |
| RBC Capital | Arun Viswanathan | $70 | $69.51 | +105.9% | Apr 21, 2022 |
| Wolfe Research | Analyst unavailable | $64 | $67.2 | +88.3% | Apr 19, 2022 |
| Mizuho Securities | Christopher Parkinson | $68 | $65.88 | +100.1% | Apr 19, 2022 |
| Deutsche Bank | David Begleiter | $66 | $63.34 | +94.2% | Mar 21, 2022 |
| Wells Fargo | Michael Sison | $72 | $59.46 | +111.8% | Jan 27, 2022 |
| Mizuho Securities | Chris Parkinson | $65 | $58.55 | +91.2% | Jan 12, 2022 |
| Citigroup | PJ Juvekar | $63 | $58.47 | +85.3% | Jan 11, 2022 |
| Barclays | Duffy Fischer | $69 | $57 | +103.0% | Oct 22, 2021 |
| Wolfe Research | Josh Silverstein | $55 | $57.54 | +61.8% | Oct 18, 2021 |
| HSBC | Sriharsha Pappu | $52 | $60.98 | +53.0% | Jun 23, 2021 |
| Argus Research | Bill Selesky | $78 | $66.99 | +129.5% | Jun 8, 2021 |
Track every rating change on DOW the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationDow Inc. is a global leader in materials science, delivering diverse solutions for key industries such as packaging, infrastructure development, mobility, and consumer products. The company's reach extends across numerous regions, including the United States, Canada, Europe, the Middle East, Africa, India, the Asia Pacific, and Latin America. Its operations are structured into three main divisions: Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings. The Packaging & Specialty Plastics segment is responsible for producing foundational chemicals like ethylene, propylene, and aromatics, along with a range of polymers including polyethylene, polyolefin elastomers, ethylene vinyl acetate, and ethylene propylene diene monomer rubbers.…
Historical context
All DOW earningsBasic Materials peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| CX CEMEX, S.A.B. de C.V. | FY2026 Q3 · Calendar Q4 2026 | +12.0% | -0.1% | CEMEX sustains growth while shifting focus to efficiency and asset pruning |
| CRS Carpenter Technology Corporation | FY2027 Q1 · Calendar Q4 2026 | +6.9% | -20.6% | CRS: Aerospace Bookings Accelerate as Guidance Holds |
| NEM Newmont Corporation | FY2026 Q3 · Calendar Q4 2026 | +12.2% | -2.6% | Newmont Holds 2026 Guidance as Projects Set Up 2027 Growth |
Latest beats and misses
Who reports nextBeat on EPS
- VZFY2026 Q3 · October 26, 2026+3.1% EPS-3.5% move
- CXFY2026 Q3 · October 26, 2026+12.0% EPS-0.1% move
- CDNSFY2026 Q3 · October 26, 2026+2.9% EPS+1.8% move
- BAHFY2027 Q2 · October 23, 2026+18.9% EPS-0.3% move
- FCNCAFY2026 Q3 · October 23, 2026+19.9% EPS+8.2% move
- FCNCNFY2026 Q3 · October 23, 2026+19.9% EPS+0.2% move
Missed on EPS
- KOFFY2026 Q3 · October 26, 2026-9.0% EPS-1.9% move
- INFYFY2027 Q2 · October 23, 2026-4.8% EPS-6.6% move
- BBDFY2026 Q3 · October 22, 2026-7.7% EPS+3.0% move
- SNAFY2026 Q3 · October 22, 2026-5.9% EPS-3.4% move
- SPOTFY2026 Q3 · October 22, 2026-11.6% EPS+11.1% move
- VRSNFY2026 Q3 · October 22, 2026-2.0% EPS-0.9% move
Get the DOW recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2024-11-10T18:38:36.707185+00:00
- Polygon adjusted daily market bars · 2026-10-27T09:00:41.961310+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-27T09:00:41.958371+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-27. For educational purposes only; not investment advice.